|
|
1246 University Ave. W., Suite 211
St. Paul, MN 55104 United States
phone:651-646-2595
fax:
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
|
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug delivery system for skin cancer |
|
| Management |
| Kevin Nickels, CEO; Stan Harpstead, CTO |
| |
|
|
| |
|
| Keywords |
| oncology, cancer, polymeric material, therapeutic molecule |
|
|
|
| Description |
|
Rubigo Therapeutics is focused on obtaining market clearance of a proprietary drug delivery platform initially targeting skin cancer through the improved delivery of an existing FDA-cleared drug, Imiquimod. Skin cancer is rising at an incidence rate of 10% per year worldwide, with US healthcare costs for non-melanoma and melanoma patients estimated at $1B and $1.9B per year, respectively. Imiquimod, which was FDA-cleared for non-melanoma skin cancer in 2006, has become well-known among dermatologists for being clinically effective for actinic keratosis (pre-squamous cell cancer), basal, and squamous cell carcinomas, as well as outside of the US for superficial melanoma. Unfortunately, current cream therapies are a source patient dissatisfaction due to extra office visits and adverse events resulting from inconsistent and over-treatment. Rubigo’s plans are to obtain market clearance through a 505(b)(2) path and to establish distribution partnerships to commercialize a proprietary transdermal drug delivery system that addresses these clinical issues by providing physicians and patients with an easy-to-apply, consistent, and controllable delivery of Imiquimod through the Company’s unique polymer film. This earlier-stage medical device company is seeking a Series A preferred investment of $3M to conduct the final pre-IND FDA studies and conduct first in human clinical studies. |
|
| Technology / Differentiation |
| The list of market opportunities and possible drug candidates that could be combined with the Rubigo Therapeutics unique material include several possibilities, the company has elected to focus its development efforts into Oncology. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members